Physician profile
Beverly J Mortimer
NPI 1053502260
$4,529.95
in general payments reported to CMS, 2019-2025
42 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,398 · 2022: $1,134 · 2023: $1,292 · 2024: $590 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,998.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,998.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $667.64 | 2021-2024 | |
| Novo Nordisk INC | $588.29 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $468.22 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $282.67 | 2021-2024 | |
| Amgen INC. | $273.40 | 2021-2024 | Repatha, Otezla |
| Pfizer INC. | $230.77 | 2021-2024 | |
| Lilly USA, LLC | $209.20 | 2021-2023 | Mounjaro, Emgality, Jardiance |
| Astellas Pharma US INC | $167.83 | 2021-2023 | Veozah |
| Axsome Therapeutics, INC. | $135.62 | 2023-2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $118.93 | 2021-2023 | Xifaxan |
| Astrazeneca Pharmaceuticals Lp | $117.85 | 2021-2023 | Fasenra, Flumist Quadrivalent, Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $107.82 | 2021-2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $90.49 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $89.91 | 2021-2023 | Verquvo, Steglujan, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.81 | 2021-2024 | Jardiance |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beverly Mortimer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.